GOLL JOHN 4

4 · Immunocore Holdings plc · Filed Feb 19, 2026

AI-generated summary of this filing

Updated Feb 19, 2026

Immunocore (IMCR) SVP/CAO John Goll Sells 698 Shares

What Happened

John Goll, SVP, Finance & CAO of Immunocore (IMCR), sold 698 shares in an open-market "sell-to-cover" transaction on Feb 18, 2026 at a weighted average price of $32.35, totaling $22,580.
The Form 4 also reports activity on Feb 17, 2026: conversion/exercise of 1,351 derivative shares (reported at $0) and grant/award entries for 7,411 and 21,252 shares (reported at $0), reflecting RSU/derivative awards and related settlements.

Key Details

Transaction dates/prices: Feb 17, 2026 (derivative exercise/conversion at $0; awards granted at $0); Feb 18, 2026 (sale of 698 shares at weighted avg $32.35; sale prices ranged $32.18–$32.72 per filing).
Value of sale: $22,580 (698 × $32.35 weighted avg).
Shares owned after the reported transactions: not specified in the excerpt of the filing provided.
Notable footnotes: (F1) Ordinary shares may be represented by ADSs (1 ADS = 1 ordinary share); (F2) the 698-share sale was a sell-to-cover to satisfy income tax liabilities on RSU vesting; (F3) the $32.35 is a weighted average (range $32.18–$32.72); (F4–F7) describe RSU/option definitions and vesting schedules for the awards and option grants.
Filing timeliness: Form 4 filed Feb 19, 2026 for transactions on Feb 17–18, 2026 — the filing appears timely.

Context

The sell-to-cover was used to satisfy tax withholding on RSU vesting and is a routine administrative sale rather than a straightforward discretionary sale of remaining holdings.
The filing shows derivative conversions/exercises and awards (RSUs/options) with vesting schedules noted in the footnotes; some shares related to those awards may vest over multiple future dates.
This activity is informational for investors tracking insider holdings and compensation-related share movements; it does not, by itself, indicate a buy/sell signal about company prospects.

Form 4

Period: 2026-02-17

SVP, FINANCE & CAO

Transactions

Exercise/Conversion
Ordinary Shares
[F1]
2026-02-17+1,351→ 1,351 total
Sale
Ordinary Shares
[F1][F2][F3]
2026-02-18$32.35/sh−698$22,580→ 653 total
Exercise/Conversion
Restricted Share Units
[F4][F5][F1]
2026-02-17−1,351→ 4,054 total
→ Ordinary Shares (1,351 underlying)
Award
Restricted Share Units
[F4][F6][F1]
2026-02-17+7,411→ 7,411 total
→ Ordinary Shares (7,411 underlying)
Award
Employee Share Option (Right to Buy)
[F7][F1]
2026-02-17+21,252→ 21,252 total
Exercise: $32.38Exp: 2036-02-16→ Ordinary Shares (21,252 underlying)

Footnotes (7)

[F1]Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share.
[F2]The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted share units ("RSUs") .
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.18 to $32.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]Each RSU represents a contingent right to receive one Ordinary Share.
[F5]On February 17, 2025, the Reporting Person was granted 5,405 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.
[F6]The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date.
[F7]25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Signature

/s/ Lily Hepworth, Attorney-in-Fact|2026-02-19

1 file